Abstract Androgen receptor (AR) plays an important role in the progression of prostate cancer and has been targeted by castration or AR-antagonists. The emergence of castration-resistant prostate cancer (CRPC) after androgen deprivation therapy (ADT) is inevitable. However. it is not entirely clear how ADT fails or how it causes resistance. https://www.ngetikin.com/special-pick-MVP4-Moisture-Vapor-Protection-Anti-Fracture-and-Noise-Reduction-Membrane-special-save/